S'abonner

Critical role of plasmacytoid dendritic cells in induction of oral tolerance - 06/06/18

Doi : 10.1016/j.jaci.2017.11.048 
Tomofumi Uto, PhD a, e, Hideaki Takagi, PhD a, e, Tomohiro Fukaya, DVM, PhD a, e, Junta Nasu, DDS a, b, Takehito Fukui, DDS a, b, Noriaki Miyanaga, MD a, c, Keiichi Arimura, DDS, PhD a, b, Takeshi Nakamura, MD a, c, Narantsog Choijookhuu, MD, PhD d, Yoshitaka Hishikawa, MD, PhD d, Katsuaki Sato, PhD a, e,
a Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan 
b Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan 
c Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan 
d Division of Histochemistry and Cell Biology, Department of Anatomy, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan 
e Japan Agency for Medical Research and Development (AMED), Tokyo, Japan 

Corresponding author: Katsuaki Sato, PhD, Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan.Division of ImmunologyDepartment of Infectious DiseasesFaculty of MedicineUniversity of Miyazaki5200 Kihara, KiyotakeMiyazaki889-1692Japan

Abstract

Background

Exposure to dietary constituents through the mucosal surface of the gastrointestinal tract generates oral tolerance that prevents deleterious T cell–mediated immunity. Although oral tolerance is an active process that involves emergence of CD4+ forkhead box p3 (Foxp3)+ regulatory T (Treg) cells in gut-associated lymphoid tissues (GALTs) for suppression of effector T (Teff) cells, how antigen-presenting cells initiate this process remains unclear.

Objective

We sought to determine the role of plasmacytoid dendritic cells (pDCs), which are known as unconventional antigen-presenting cells, in establishment of oral tolerance.

Methods

GALT-associated pDCs in wild-type mice were examined for their ability to induce differentiation of CD4+ Teff cells and CD4+Foxp3+ Treg cells in vitro. Wild-type and pDC-ablated mice were fed oral antigen to compare their intestinal generation of CD4+Foxp3+ Treg cells and induction of oral tolerance to protect against Teff cell–mediated allergic inflammation.

Results

GALT-associated pDCs preferentially generate CD4+Foxp3+ Treg cells rather than CD4+ Teff cells, and such generation requires an autocrine loop of TGF-β for its robust production. A deficiency of pDCs abrogates antigen-specific de novo generation of CD4+Foxp3+ Treg cells occurring in GALT after antigenic feeding. Furthermore, the absence of pDCs impairs development of oral tolerance, which ameliorates the progression of delayed-type hypersensitivity and systemic anaphylaxis, as well as allergic asthma, accompanied by an enhanced antigen-specific CD4+ Teff cell response and antibody production.

Conclusion

pDCs are required for establishing oral tolerance to prevent undesirable allergic responses, and they might serve a key role in maintaining gastrointestinal immune homeostasis.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Mucosal immunity, oral tolerance, dendritic cells, regulatory T cells, allergy

Abbreviations used : ALDH, APC, BALF, cDC, CFA, DC, DT, DTH, EGFP, Foxp3, GALT, IDO, iTreg, LP, MLN, OVA, OVAp, pDC, PGN, RA, siLP, TCR, Teff, TLR, Treg


Plan


 Supported by a Grant-in-Aid for Challenging Exploratory Research (to K.S.) and for Young Scientists (B; to T.U. T.F., and H.T.) from the Ministry of Education, Science and Culture of Japan; the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development (AMED; to K.S.); the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K.S.); the Uehara Memorial Foundation (to K.S. and H.T.); the Takeda Science Foundation (to H.T. and T.F.); the Novartis Foundation (Japan) for the Promotion of Science (to H.T.); the Kato Memorial Bioscience Foundation (to H.T.); the Nagao Memorial Fund (to H.T.); the Daiichi Sankyo Foundation of Life Science (to K.S.); the Naito Foundation (to K.S.); the GSK Japan Research Grant (to T.F. and H.T.); and Bristol-Myers Squibb Foundation Grants (to K.S.).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2018  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 141 - N° 6

P. 2156 - juin 2018 Retour au numéro
Article précédent Article précédent
  • Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations
  • Alexander Vargas-Hernández, Emily M. Mace, Ofer Zimmerman, Christa S. Zerbe, Alexandra F. Freeman, Sergio Rosenzweig, Jennifer W. Leiding, Troy Torgerson, Matthew C. Altman, Edith Schussler, Charlotte Cunningham-Rundles, Ivan K. Chinn, Alexandre F. Carisey, Imelda C. Hanson, Nicholas L. Rider, Steven M. Holland, Jordan S. Orange, Lisa R. Forbes
| Article suivant Article suivant
  • Phosphatase wild-type p53-induced phosphatase 1 controls the development of TH9 cells and allergic airway inflammation
  • Peng Wang, Huiting Su, Lianjun Zhang, Hui Chen, Xuelian Hu, Fan Yang, Jun Lv, Lianfeng Zhang, Yong Zhao

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.